Corrigendum to “Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials” [Urol Sci (2015) 41–48]

Corrigendum to “Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials” [Urol Sci (2015) 41–48]

Bibliographic Details
Main Authors:	Hann-Chorng Kuo, Ho-Hsiung Lin, Hong-Jeng Yu, Chen-Li Cheng, Man-Jung Hung, Alex Tong-Long Lin
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-06-01
Series:	Urological Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S1879522615003747

Similar Items

Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials
by: Hann-Chorng Kuo, et al.
Published: (2015-03-01)

Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients
by: Chung-Cheng Wang, et al.
Published: (2019-01-01)

Mirabegron, a breakthrough in overactive bladder syndrome?
by: Almudena Maestro Nombela, et al.
Published: (2017-05-01)

Mirabegron escalation to 50 mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder
by: Chun-Hou Liao, et al.
Published: (2019-03-01)

Corrigendum to “A pilot study of fesoterodine in the management of men with refractory overactive bladder symptoms after surgery for bladder outlet obstruction” [Urol Sci (2015) 38–40]
by: Bilal Chughtai, et al.
Published: (2015-06-01)

Patient utilization survey of mirabegron prescribed for overactive bladder
by: Päivi Rahkola-Soisalo, et al.
Published: (2019-03-01)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
by: Sharaf A, et al.
Published: (2017-02-01)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
by: Marilena Gubbiotti, et al.
Published: (2019-01-01)

Preliminary experience and possible predictors of successful mirabegron treatment for overactive bladder
by: Tsai-Feng Chen, et al.
Published: (2017-09-01)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
by: Makhani A, et al.
Published: (2020-04-01)

Effect of mirabegron in patients with myasthenia gravis disease and overactive bladder symptoms
by: M.G. Çulha, et al.
Published: (2020-07-01)

Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder
by: Mehmet Solakhan, et al.
Published: (2019-09-01)

Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?
by: Ömer Acar, et al.
Published: (2019-06-01)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
by: Andersson KE
Published: (2013-04-01)

Re: Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder
by: Sinharib Çitgez
Published: (2016-12-01)

Mirabegron: A first-in-class beta-3 agonist for overactive bladder
by: Suruchi Aditya, et al.
Published: (2015-01-01)

Individualizing medical treatment of overactive bladder
by: Hann-Chorng Kuo
Published: (2018-01-01)

Clinical use of the β adrenoceptor agonist mirabegron in patients with overactive bladder syndrome
by: Monika Vij, et al.
Published: (2015-10-01)

Mirabegron: a review of recent data and its prospects in the management of overactive bladder
by: Emilio Sacco, et al.
Published: (2012-12-01)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
by: Sara J. Allison, et al.
Published: (2018-12-01)

Mirabegron: the review of current knowledge of safety and efficacy in the relief of overactive bladder symptoms
by: Tomasz Aleksiewicz, et al.
Published: (2018-08-01)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
by: Yankai Xu, et al.
Published: (2017-09-01)

Treatment of overactive bladder: Past, present, and future
by: Hann-Chorng Kuo
Published: (2015-03-01)

Mirabegron (25mg) in patients with overactive bladder is effective and safe in real life practice
by: Yuan Chi Shen, et al.
Published: (2016-06-01)

Mirabegron for Overactive Bladder: A Novel, First-in-Class β3- Agonist Therapy
by: Mohammed Imran, et al.
Published: (2013-09-01)

Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder
by: Cheng-Ling Lee, et al.
Published: (2020-01-01)

Mirabegron does not decrease urinary neurotrophin's levels in overactive bladder patients despite symptomatic improvement
by: Ana Sara dos Santos Ferreira
Published: (2019)

Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: A pilot study
by: Marilena Gubbiotti, et al.
Published: (2019-05-01)

The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder
by: Ganesh Thiagamoorthy, et al.
Published: (2016-02-01)

Perspectives on mirabegron in the treatment of overactive bladder syndrome: A new beta-3 adrenoceptor agonist
by: Chia-Hao Kuei, et al.
Published: (2015-03-01)

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
by: Lee RT, et al.
Published: (2013-10-01)

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
by: Seong Cheol Kim, et al.
Published: (2021-05-01)

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
by: Sheng-Mou Hsiao, et al.
Published: (2016-01-01)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
by: Jameel Nazir, et al.
Published: (2018-09-01)

The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study
by: A. Zachariou, et al.
Published: (2018-06-01)

Mirabegron &ndash; a selective &szlig;3-adrenoreceptor agonist for the treatment of overactive bladder
by: Bhide AB, et al.
Published: (2012-07-01)

Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)
by: Tomas L. Griebling, et al.
Published: (2020-03-01)

Mirabegron add-on therapy to tamsulosin in men with overactive bladder: Post-hoc analyses of efficacy from the MATCH study
by: H. Kakizaki, et al.
Published: (2020-07-01)

Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence
by: Mete Özkidik, et al.

The Overactive Bladder Symptom Score, International Prostate Symptom Score–Storage Subscore, and Urgency Severity Score in Patients With Overactive Bladder and Hypersensitive Bladder: Which Scoring System is Best?
by: Fei-Chi Chuang, et al.
Published: (2018-06-01)